SG11201509729YA - Use of high dose pridopidine for treating huntington's disease - Google Patents
Use of high dose pridopidine for treating huntington's diseaseInfo
- Publication number
- SG11201509729YA SG11201509729YA SG11201509729YA SG11201509729YA SG11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA SG 11201509729Y A SG11201509729Y A SG 11201509729YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- high dose
- treating huntington
- dose pridopidine
- pridopidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837928P | 2013-06-21 | 2013-06-21 | |
US201361877832P | 2013-09-13 | 2013-09-13 | |
PCT/US2014/043204 WO2014205229A1 (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201509729YA true SG11201509729YA (en) | 2015-12-30 |
Family
ID=52105289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201509729YA SG11201509729YA (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Country Status (24)
Country | Link |
---|---|
US (1) | US10322119B2 (ja) |
EP (1) | EP3010506B1 (ja) |
JP (1) | JP2016523862A (ja) |
KR (1) | KR102316933B1 (ja) |
CN (1) | CN105592848A (ja) |
AU (1) | AU2014281414A1 (ja) |
BR (1) | BR112015029918A2 (ja) |
CA (1) | CA2913781C (ja) |
CL (1) | CL2015003690A1 (ja) |
DK (1) | DK3010506T3 (ja) |
EA (1) | EA201690069A1 (ja) |
ES (1) | ES2879631T3 (ja) |
HK (1) | HK1221646A1 (ja) |
HU (1) | HUE054783T2 (ja) |
IL (1) | IL242804B (ja) |
MX (1) | MX2015017307A (ja) |
PE (2) | PE20160195A1 (ja) |
PH (1) | PH12015502691A1 (ja) |
PL (1) | PL3010506T3 (ja) |
SG (1) | SG11201509729YA (ja) |
TW (1) | TW201529069A (ja) |
UA (1) | UA122999C2 (ja) |
UY (1) | UY35624A (ja) |
WO (1) | WO2014205229A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
MX2013002453A (es) | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
MX2016009427A (es) * | 2014-01-22 | 2016-12-08 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada. |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
EP3590512A1 (en) * | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
WO2017147366A1 (en) | 2016-02-24 | 2017-08-31 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
AU2017315781B2 (en) * | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
CA3151507C (en) * | 2016-08-24 | 2024-05-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
CA3036842A1 (en) * | 2016-09-15 | 2018-03-22 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for the treatment of anxiety and depression |
CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
IL268125B2 (en) | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
WO2019036358A1 (en) * | 2017-08-14 | 2019-02-21 | Teva Pharmaceuticals International Gmbh | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE |
EP3675830A1 (en) * | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
MX2020002645A (es) | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
WO2020250234A1 (en) * | 2019-06-12 | 2020-12-17 | Prilenia Neurotherapeutics Ltd. | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof |
CN114727761A (zh) * | 2019-09-17 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 患有运动障碍的患者的个性化保健的改善 |
WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
EP1713486A4 (en) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
MX2013002453A (es) | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
MX2014011971A (es) | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
WO2014052933A1 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
MX2016009427A (es) | 2014-01-22 | 2016-12-08 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada. |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
CA3151507C (en) * | 2016-08-24 | 2024-05-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
CA3036842A1 (en) | 2016-09-15 | 2018-03-22 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for the treatment of anxiety and depression |
WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
-
2014
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 MX MX2015017307A patent/MX2015017307A/es unknown
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en active Application Filing
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active IP Right Grant
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
-
2016
- 2016-08-16 HK HK16109788.9A patent/HK1221646A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EA201690069A1 (ru) | 2016-06-30 |
IL242804B (en) | 2022-02-01 |
BR112015029918A2 (pt) | 2017-07-25 |
ES2879631T3 (es) | 2021-11-22 |
KR20160055122A (ko) | 2016-05-17 |
PE20160195A1 (es) | 2016-05-14 |
HUE054783T2 (hu) | 2021-09-28 |
WO2014205229A8 (en) | 2015-04-09 |
PL3010506T3 (pl) | 2021-11-02 |
KR102316933B1 (ko) | 2021-10-26 |
DK3010506T3 (da) | 2021-07-12 |
PH12015502691A1 (en) | 2016-03-14 |
TW201529069A (zh) | 2015-08-01 |
PE20170302A1 (es) | 2017-03-31 |
EP3010506A1 (en) | 2016-04-27 |
AU2014281414A1 (en) | 2016-01-21 |
US10322119B2 (en) | 2019-06-18 |
EP3010506A4 (en) | 2017-02-08 |
MX2015017307A (es) | 2016-08-03 |
HK1221646A1 (zh) | 2017-06-09 |
US20140378508A1 (en) | 2014-12-25 |
JP2016523862A (ja) | 2016-08-12 |
UY35624A (es) | 2015-01-30 |
CA2913781C (en) | 2022-05-10 |
WO2014205229A1 (en) | 2014-12-24 |
CN105592848A (zh) | 2016-05-18 |
CA2913781A1 (en) | 2014-12-24 |
UA122999C2 (uk) | 2021-02-03 |
EP3010506B1 (en) | 2021-05-12 |
CL2015003690A1 (es) | 2016-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201509729YA (en) | Use of high dose pridopidine for treating huntington's disease | |
IL266648B (en) | A method for treating Parkinson's disease | |
ZA201608108B (en) | Huntington's disease therapeutic compounds | |
HK1225305A1 (zh) | 治療腦疾病的方法和組合物 | |
EP3019523A4 (en) | METHODS OF TREATING ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE | |
IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
HK1220418A1 (zh) | 治療呼吸系統疾病的方法及為此而製的製劑 | |
EP3068905A4 (en) | Methods and compositions for treating huntington's disease | |
ZA201406209B (en) | Methods and compositions for treating huntington's disease | |
HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
EP2968321A4 (en) | COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES | |
IL239851A0 (en) | Methods and compositions for treating diseases that act to remove myelin | |
HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
PL2959903T3 (pl) | Lek do leczenia chorób oczu | |
EP3013834A4 (en) | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES | |
EP3013334A4 (en) | SUBSTITUTED BENZOFURAN COMPOUNDS AND THEIR METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES | |
IL243637B (en) | PPAR-sparing compounds for the treatment of metabolic diseases | |
HK1218883A1 (zh) | 對神經毒劑的暴露的治療 | |
HK1224215A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
IL241482A0 (en) | A method for treating Parkinson's disease | |
GB201310101D0 (en) | Treatment of freidreich's ataxia | |
GB201321628D0 (en) | Treatment of disease |